Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycinebetaine SCHEMBL1646004 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11GSRGRM8GRM6 | |
| Methionine SCHEMBL5484912 | 0.90 | RNPEP (0.39) | PTGS1SLC7A11ANPEPENPEP | |
| Glycinebetaine SCHEMBL18107967 | 0.86 | PTGS1 (0.59) | PTGS1SLC7A11GSRGRM8GRM6 | |
| Norvaline SCHEMBL20476465 | 0.84 | SLC1A2 (0.46) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Glycinebetaine SCHEMBL272555 | 0.84 | GSR (0.39) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL2504670 | 0.83 | GRM8 (0.62) | GSRGRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL272113 | 0.83 | GRM8 (0.62) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL8995461 | 0.81 | GRM8 (0.60) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Ornithine Aketoglutarate SCHEMBL272917 | 0.81 | GSR (0.56) | GSRCYP1A2CPT2CPT1ABLM | |
| Ornithine SCHEMBL1539161 | 0.81 | GSR (0.56) | GSRCYP1A2CPT2CPT1ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1249225-C | Preparation and application of recombined human betaine homocysteine methyl transferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2006-04-05 | — | — | CN | claimed |
| US-20220229077-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2022-07-21 | — | — | US | disclosed |
| EP-2773355-B1 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN | SOUTH ALABAMA MEDICAL SCIENCE FOUND (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210346319-A1 | Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-11 | — | — | US | disclosed |
| WO-2020072311-A1 | PHARMACEUTICAL COMPOSITIONS OF R-(+)-PROPRANOLOL IN ENANTIOMERIC EXCESS AND THERAPEUTIC USES RELATED THERETO | EMORY UNIVERSITY (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2309876-B1 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE | NESTLE SA (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3612214-A1 | OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA | The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200049722-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2020-02-13 | — | — | US | disclosed |
| EP-3516389-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | Precision Medicine Holdings Pty Ltd (AU) | 2019-07-31 | — | — | EP | disclosed |
| US-10357496-B2 | Methods, formulations, and kits for rapidly repleting folate levels in women | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 2019-07-23 | — | — | US | disclosed |
| CN-1807634-A | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | BASF AG (DE) | 2006-07-26 | — | — | CN | disclosed |
| US-7060444-B1 | Zone 3 necrosis associated markers and method of use thereof | CURAGEN CORPORATION (US) | 2006-06-13 | — | — | US | disclosed |
| CN-1249225-C | Preparation and application of recombined human betaine homocysteine methyl transferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2006-04-05 | — | — | CN | disclosed |
| CN-1249225-C | Preparation and application of recombined human betaine homocysteine methyl transferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2006-04-05 | — | — | CN | disclosed |
| CN-1249225-C | Preparation and application of recombined human betaine homocysteine methyl transferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2006-04-05 | — | — | CN | disclosed |
| WO-2005058300-A1 | METHOD OF TREATING ELEVATED PLASMA HOMOCYSTEINE LEVELS IN ESRD PATIENTS | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| CN-1408854-A | Preparation and application of recombinant human betaine homocysteine methyltransferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2003-04-09 | — | — | CN | disclosed |
| CN-1408854-A | Preparation and application of recombinant human betaine homocysteine methyltransferase | INST OF HYGIENICS AND ENVIRONM (CN) | 2003-04-09 | — | — | CN | disclosed |
| WO-2001002600-A2 | DETECTION OF ANALYTES USING ATTENUATED ENZYMES | GENERAL ATOMICS (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5428063-A | For treating or preventing fatty infiltration, the first stage of cirrhosis | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1995-06-27 | — | — | US | disclosed |